At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓High-risk stage III melanoma defined as recurrent nodal metastasis, clinically detectable nodal metastasis, or metastatic involvement of more than one nodal basin
- ✓Histologically confirmed stage III melanoma per AJCC 8th edition
- ✓BRAF mutation status documented via CLIA-approved test (Arms A and B only)
- ✕Prior systemic anti-cancer therapy for melanoma including chemotherapy, targeted therapy, or immunotherapy (anti-PD-1/PD-L1), except adjuvant interferon, IL-2, GM-CSF, or vaccine therapies discontinued ≥28 days prior
- ✕History of non-nodal melanoma metastasis or CNS lesions
- ✕Active malignancy other than melanoma, or prior malignancy within 3 years (with specified exceptions)
- ✕Prior allogeneic stem cell or solid organ transplantation
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Cobimetinib, and 2 other interventions for Clinical Stage III Cutaneous Melanoma AJCC v8 and 5 related conditions. Completed, enrolled 64 participants across 3 sites.
Detailed Summary
This trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobimetinib, and atezolizumab may work better in treating high-risk stage III melanoma. Giving atezolizumab and tiragolumab together may also work better in treating high-risk stage III melanoma.
Study Details
Timeline
Interventions
Given IV
Given PO
Given IV
Given PO